Company: RGNX
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001193125-25-053998
Chunk: 9

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 9
---
 These risks and uncertainties are not the only risks and uncertainties we face.
Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any prospectus supplement or any additional
risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part of your
investment.

USE OF PROCEEDS

Unless otherwise indicated in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities offered
under this prospectus for general corporate purposes, which may include, but are not limited to, providing financing for clinical trials, capital expenditures, additions to working capital, development of our product candidate pipeline, general and
administrative expenses or other corporate obligations. We may use a portion of the net proceeds to pay off outstanding indebtedness, if any, or acquire or invest in businesses, products or technologies. We will set forth in the applicable
prospectus supplement our intended use for the net proceeds received from the sale of any securities. Pending the use of such proceeds, we intend to invest the net proceeds in short-term, investment grade, interest-bearing instruments.

3

DESCRIPTION OF CAPITAL STOCK The following description is a general summary of the terms of the shares of common stock and shares of preferred stock that we may issue. The description below and in any prospectus supplement does not include all of the terms of the shares of common stock or shares of preferred stock and should be read together with our restated certificate of incorporation and amended and restated bylaws, copies of which have been filed previously with the SEC. For more information on how you can obtain copies of our restated certificate of incorporation and amended and restated bylaws, see “Where You Can Find More Information.” Our authorized capital stock consists of 110,000,000 shares, with a par value of $0.0001 per share, of which:

| • |     | 100,000,000 shares are designated as common stock; and |

| • |     | 10,000,000 shares are designated as preferred stock. |

As of December 31, 2024, there were 49,549,399 shares of the registrant’s common stock, par value $0.0001 per share, issued and outstanding. No shares of preferred stock were outstanding as